Treatment of neonatal sepsis with intravenous immune globulin

INIS Collaborative Group; Peter Brocklehurst; Barbara Farrell; Andrew King; Edmund Juszczak; Brian Darlow; Khalid Haque; Alison Salt; Ben Stenson; William Tarnow-Mordi

doi:10.1056/NEJMoa1100441

Treatment of neonatal sepsis with intravenous immune globulin

INIS Collaborative Group, Peter Brocklehurst, Barbara Farrell, Andrew King, Edmund Juszczak, Brian Darlow, Khalid Haque, Alison Salt, Ben Stenson, William Tarnow-Mordi

College of Medicine and Veterinary Medicine

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Neonatal sepsis is a major cause of death and complications despite antibiotic treatment. Effective adjunctive treatments are needed. Newborn infants are relatively deficient in endogenous immunoglobulin. Meta-analyses of trials of intravenous immune globulin for suspected or proven neonatal sepsis suggest a reduced rate of death from any cause, but the trials have been small and have varied in quality.

Original language	English
Pages (from-to)	1201-11
Number of pages	11
Journal	New England Journal of Medicine
Volume	365
Issue number	13
DOIs	https://doi.org/10.1056/NEJMoa1100441
Publication status	Published - 29 Sept 2011

Keywords / Materials (for Non-textual outputs)

Double-Blind Method
Immunologic Factors
Humans
Infant, Newborn
Recurrence
Drug Therapy, Combination
Staphylococcal Infections
Anti-Bacterial Agents
Risk
Gram-Positive Bacterial Infections
Sepsis
Immunoglobulins, Intravenous
Female
Male

Access to Document

10.1056/NEJMoa1100441

Cite this

@article{161abbd0df1a4f679f0eb21fa1ecf8de,

title = "Treatment of neonatal sepsis with intravenous immune globulin",

abstract = "Neonatal sepsis is a major cause of death and complications despite antibiotic treatment. Effective adjunctive treatments are needed. Newborn infants are relatively deficient in endogenous immunoglobulin. Meta-analyses of trials of intravenous immune globulin for suspected or proven neonatal sepsis suggest a reduced rate of death from any cause, but the trials have been small and have varied in quality.",

keywords = "Double-Blind Method, Immunologic Factors, Humans, Infant, Newborn, Recurrence, Drug Therapy, Combination, Staphylococcal Infections, Anti-Bacterial Agents, Risk, Gram-Positive Bacterial Infections, Sepsis, Immunoglobulins, Intravenous, Female, Male",

author = "{INIS Collaborative Group} and Peter Brocklehurst and Barbara Farrell and Andrew King and Edmund Juszczak and Brian Darlow and Khalid Haque and Alison Salt and Ben Stenson and William Tarnow-Mordi",

year = "2011",

month = sep,

day = "29",

doi = "10.1056/NEJMoa1100441",

language = "English",

volume = "365",

pages = "1201--11",

journal = "New England Journal of Medicine",

issn = "1533-4406",

publisher = "MASSACHUSETTS MEDICAL SOC",

number = "13",

}

TY - JOUR

T1 - Treatment of neonatal sepsis with intravenous immune globulin

AU - INIS Collaborative Group

AU - Brocklehurst, Peter

AU - Farrell, Barbara

AU - King, Andrew

AU - Juszczak, Edmund

AU - Darlow, Brian

AU - Haque, Khalid

AU - Salt, Alison

AU - Stenson, Ben

AU - Tarnow-Mordi, William

PY - 2011/9/29

Y1 - 2011/9/29

N2 - Neonatal sepsis is a major cause of death and complications despite antibiotic treatment. Effective adjunctive treatments are needed. Newborn infants are relatively deficient in endogenous immunoglobulin. Meta-analyses of trials of intravenous immune globulin for suspected or proven neonatal sepsis suggest a reduced rate of death from any cause, but the trials have been small and have varied in quality.

AB - Neonatal sepsis is a major cause of death and complications despite antibiotic treatment. Effective adjunctive treatments are needed. Newborn infants are relatively deficient in endogenous immunoglobulin. Meta-analyses of trials of intravenous immune globulin for suspected or proven neonatal sepsis suggest a reduced rate of death from any cause, but the trials have been small and have varied in quality.

KW - Double-Blind Method

KW - Immunologic Factors

KW - Humans

KW - Infant, Newborn

KW - Recurrence

KW - Drug Therapy, Combination

KW - Staphylococcal Infections

KW - Anti-Bacterial Agents

KW - Risk

KW - Gram-Positive Bacterial Infections

KW - Sepsis

KW - Immunoglobulins, Intravenous

KW - Female

KW - Male

U2 - 10.1056/NEJMoa1100441

DO - 10.1056/NEJMoa1100441

M3 - Article

C2 - 21962214

SN - 1533-4406

VL - 365

SP - 1201

EP - 1211

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 13

ER -

Treatment of neonatal sepsis with intravenous immune globulin

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this